PURPOSE: Acalabrutinib, a second-generation Bruton tyrosine kinase inhibitor, has efficacy in relapsed and refractory diffuse large B-cell lymphoma (DLBCL). The ACCEPT trial investigated the safety and efficacy of acalabrutinib in addition to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP) in first-line therapy. METHODS: In this phase Ib/II non-randomized study, eligible patients were treatment naïve, aged 16 years or older with a histologic diagnosis of DLBCL. The primary end point of the trial was to determine the recommended phase II dose (RP2D) of acalabrutinib in combination with R-CHOP and assess the safety and overall response rate (ORR). RESULTS: Between 2017 and 2020, 38 patients were enrolled. Of those enrolled, seven were ineligible. Median age was 64 years (range, 24-80); 76% were stage III/IV; 55% International Prognostic Index ≥3. No dose-limiting toxicities were observed, and the RP2D of acalabrutinib was 100 mg twice daily. The most common grade ≥3 adverse events at RP2D were neutropenia (37%), febrile neutropenia (13%), and diarrhea (10%). Eighty-eight percent of patients received six cycles of R-CHOP. Age did not compromise treatment delivery. At the RP2D, 20/24 (83%) patients had a complete response and three (12.5%) a partial response (ORR, 96% [95% CI, 79 to 100]). With median 30-months follow-up, the 24-month progression-free survival was 95% (95% CI, 68 to 99), event-free survival was 90% (95% CI, 66 to 97), and overall survival was 96% (95% CI, 73 to 99). CONCLUSION: The combination of acalabrutinib with R-CHOP is well tolerated, including in those older than 65 years. High efficacy in DLBCL was observed, regardless of cell-of-origin subtype. These findings support further investigation of this combination in a randomized trial.